What evidence gaps are holding back ketamine maintenance therapy?

Does ketamine maintenance therapy actually work for depression and anxiety?

Yes, the evidence suggests it can sustain symptom relief, but the data is strongest for short-term effects. A 2022 systematic review of 41 studies (including 3 randomized controlled trials) found that intravenous, intranasal, oral, and possibly intramuscular and subcutaneous maintenance ketamine effectively prolongs antidepressant effects in treatment-resistant depression [8]. However, the authors caution that most studies are small, open-label, or case reports, limiting confidence in long-term efficacy.

For anxiety disorders, the picture is similar. A 2021 meta-analysis of 6 acute randomized trials found that ketamine significantly improved symptoms in social anxiety disorder (odds ratio of response: 28.94, meaning nearly 29 times more likely to respond than placebo), but not in PTSD (odds ratio: 2.03, not statistically significant) [3]. The same review noted that maintenance therapy was associated with sustained anxiolytic effects and improved functioning, but this came from open-label studies, not controlled trials [3].

A 2023 meta-analysis of 14 studies found that a single ketamine dose reduced anxiety scores compared to placebo at 24 hours (moderate effect) and at 7-14 days (small-to-moderate effect), but the authors explicitly call for future studies on maintenance therapy [1]. This highlights a key gap: we have good evidence for acute effects, but much less for repeated dosing over months or years.

What specific evidence gaps are holding back maintenance therapy?

The biggest gap is the lack of standardized dosing protocols. A 2025 systematic review of 11 studies on ketamine maintenance for depression found that regular dosing schedules (e.g., weekly or biweekly) led to lower relapse rates (27.3%) compared to variable schedules (45.6%), but protocols varied widely across studies [4]. Similarly, a case report on fibromyalgia used a maintenance regimen of two monthly infusions, but the authors note that dosing is not standardized [7]. Without consensus on dose, frequency, and route (IV vs intranasal vs oral), clinicians cannot reliably replicate results.

Long-term safety data is sparse. A 2022 review concluded that tachyphylaxis (loss of effect), cognitive impairment, addiction, and serious renal/urinary problems seem uncommon, but this is based on limited follow-up [8]. The same review calls for controlled studies with long-term follow-up and sufficient power to assess these risks [8]. A 2025 review reported a 7.2% discontinuation rate due to adverse events, which were mostly mild to moderate, but again, follow-up was short [4].

We also lack reliable predictors of who will benefit. A 2023 open-label trial of 75 patients found that 40% of those who did not respond after a single ketamine infusion went on to achieve remission after three infusions, while only 20% of non-responders after two infusions did [5]. This suggests early response is a clue, but not a guarantee. The same study found no link between remission and age, gender, or BMI [5]. A 2025 review identified younger age (<45) and shorter depression duration (<2 years) as predictors of better response, but these findings need replication [4].

Is the evidence stronger for PTSD or chronic pain conditions?

For PTSD, one small but rigorous randomized controlled trial of 30 patients found that six ketamine infusions over 2 weeks significantly reduced PTSD symptoms compared to a psychoactive placebo (midazolam), with 67% of ketamine patients responding vs 20% of controls [2]. The median time to loss of response after the 2-week course was 27.5 days, suggesting maintenance would be needed [2]. However, this is the only such trial, and the sample is small. A 2021 meta-analysis found that ketamine did not significantly improve PTSD symptoms across multiple trials (odds ratio 2.03, not significant), though this may reflect the small number of studies [3].

For chronic pain, the evidence is even thinner. A case report on fibromyalgia described a patient who achieved >50% pain relief after 9 IV ketamine sessions and was maintained on two monthly infusions, but this is a single case [7]. A pediatric ICU study found that continuous ketamine infusion helped spare opioids and benzodiazepines in 71% of patients, but this was in a different population (acutely ill children) and not for chronic pain maintenance [6]. No large controlled trials of maintenance ketamine for chronic pain were identified in the provided papers.

About These Sources

This answer is built on 8 peer-reviewed studies — published from 2021 to 2025, 1 from 2024 or later, 5 in Q1 journals, collectively cited 438 times — selected as the most relevant from 9 studies that passed quality screening, drawn from 54 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions